1. KS05.6.A Oral DNA vaccination targeting VEGFR2 combined with the anti-PD-L1 antibody avelumab in patients with progressive glioblastoma - final results. NCT03750071. (5th September 2022) Authors: Wick, W; Wick, A; Chinot, O; Sahm, F; von Deimling, A; Jungk, C; Mansour, M; Podola, L; Lubenau, H; Platten, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P01.031 VXM01 phase I study in patients with progressive glioblastoma - final results. (19th September 2018) Authors: Wick, W; Wick, A; Sahm, F; Riehl, D; von Deimling, A; Bendszus, M; Mickingereder, P; Beckhove, P; Schmitz Winnenthal, F; Jungk, C; Wieckoswski, S; Keller, A; Podola, L; Herold-Mende, C; Lubenau, H; Unterberg, A; Platten, M J Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗